- Report
- February 2026
- 282 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 172 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 483 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 478 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 381 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 374 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 184 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 383 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 272 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 291 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 269 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 376 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 177 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 118 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 135 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 390 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 214 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 453 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- August 2025
- 196 Pages
Global
From €3450EUR$3,939USD£2,994GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more